ZAMAGNI, ELENA
 Distribuzione geografica
Continente #
NA - Nord America 1.436
EU - Europa 760
AS - Asia 171
AF - Africa 23
SA - Sud America 16
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 1
Totale 2.415
Nazione #
US - Stati Uniti d'America 1.412
IT - Italia 290
FR - Francia 152
DE - Germania 53
CN - Cina 51
GB - Regno Unito 51
IE - Irlanda 46
IN - India 25
AT - Austria 20
CA - Canada 20
JP - Giappone 19
NL - Olanda 19
BG - Bulgaria 17
RU - Federazione Russa 13
UA - Ucraina 12
VN - Vietnam 12
FI - Finlandia 11
RO - Romania 11
HK - Hong Kong 10
ES - Italia 8
GR - Grecia 8
CZ - Repubblica Ceca 7
SE - Svezia 7
TW - Taiwan 7
ZA - Sudafrica 7
AE - Emirati Arabi Uniti 6
AU - Australia 6
BE - Belgio 6
CL - Cile 6
IL - Israele 6
KR - Corea 6
PT - Portogallo 6
ID - Indonesia 5
MA - Marocco 5
PL - Polonia 5
TR - Turchia 5
BR - Brasile 4
HR - Croazia 4
SA - Arabia Saudita 4
TN - Tunisia 4
AR - Argentina 3
IQ - Iraq 3
MX - Messico 3
NO - Norvegia 3
CH - Svizzera 2
CY - Cipro 2
DZ - Algeria 2
HU - Ungheria 2
IR - Iran 2
NZ - Nuova Zelanda 2
PE - Perù 2
SG - Singapore 2
SN - Senegal 2
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BJ - Benin 1
CO - Colombia 1
CR - Costa Rica 1
DK - Danimarca 1
EE - Estonia 1
EG - Egitto 1
IS - Islanda 1
JO - Giordania 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MW - Malawi 1
QA - Qatar 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
SY - Repubblica araba siriana 1
TH - Thailandia 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 2.415
Città #
Ashburn 352
Santa Cruz 96
Fairfield 86
Houston 68
Seattle 62
Buffalo 58
Dublin 43
Milan 36
Bologna 31
Chicago 28
Wilmington 28
Ann Arbor 27
Paris 25
Boardman 24
Woodbridge 23
San Diego 21
Cambridge 20
Los Angeles 17
Sofia 17
Southend 16
Vienna 16
New York 14
Mountain View 13
Chandler 11
Helsinki 10
Ottawa 10
Provo 10
Bremen 9
Bucharest 9
Council Bluffs 9
Genoa 9
Rome 9
Florence 8
London 8
San Francisco 8
Bengaluru 7
Catania 7
Fabriano 7
Guangzhou 7
Shanghai 7
Athens 6
Boston 6
Cedar Knolls 6
Clearwater 6
Muizenberg 6
Amsterdam 5
Bari 5
Beijing 5
Bischheim 5
Duncan 5
Frankfurt am Main 5
Madison 5
Milpitas 5
Riva 5
Santiago 5
Wuhan 5
Atlanta 4
Burnaby 4
Hamburg 4
Herndon 4
Ho Chi Minh City 4
Istanbul 4
Kaohsiung City 4
Moscow 4
Palermo 4
Rimini 4
San Marco Argentano 4
Stockholm 4
Tokyo 4
Turin 4
West Jordan 4
Ahmedabad 3
Auburn 3
Brookline 3
Brussels 3
Büdelsdorf 3
Cardiff 3
Como 3
Dalmine 3
Deiva Marina 3
Dong Ket 3
Las Vegas 3
Munich 3
Naples 3
Oslo 3
Parma 3
Pavia 3
Phoenix 3
Redmond 3
Saint Petersburg 3
Salt Lake City 3
Seoul 3
Véry 3
Alimos 2
Auckland 2
Austin 2
Bellaria-Igea Marina 2
Bergamo 2
Berlin 2
Boulder 2
Totale 1.491
Nome #
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†, file e1dcb338-8d5a-7715-e053-1705fe0a6cc9 359
18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease, file e1dcb336-c0cf-7715-e053-1705fe0a6cc9 288
Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma, file e1dcb336-5551-7715-e053-1705fe0a6cc9 185
Diagnosis, treatment, and response assessment in solitary plasmacytoma: Updated recommendations from a European Expert Panel, file e1dcb335-1a90-7715-e053-1705fe0a6cc9 137
Glucose metabolism quantified by suvmax on baseline fdg-pet/ct predicts survival in newly diagnosed multiple myeloma patients: Combined harmonized analysis of two prospective phase iii trials, file e1dcb337-59dd-7715-e053-1705fe0a6cc9 133
Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide, file e1dcb334-7b0c-7715-e053-1705fe0a6cc9 110
Peripheral neuropathy induced by subcutaneous bortezomib-based induction therapy for newly diagnosed multiple myeloma., file e1dcb332-a917-7715-e053-1705fe0a6cc9 92
Functional imaging for therapeutic assessment and minimal residual disease detection in multiple myeloma, file b1c1eff4-d6ee-4d3a-8617-1755ac01f131 91
Inverse probability weighting to estimate causal effect of a singular phase in a multiphase randomized clinical trial for multiple myeloma, file e1dcb32e-cfc5-7715-e053-1705fe0a6cc9 91
MRD in multiple myeloma: more questions than answers?, file e1dcb334-ffc1-7715-e053-1705fe0a6cc9 85
Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group, file e1dcb334-ffbf-7715-e053-1705fe0a6cc9 76
A prospective observational study to assess clinical decision-making, prognosis, quality of life and satisfaction with care in patients with relapsed/refractory multiple myeloma: the CLARITY study protocol, file e1dcb335-50a2-7715-e053-1705fe0a6cc9 75
Interest of pet imaging in multiple myeloma, file e1dcb334-6f24-7715-e053-1705fe0a6cc9 68
Treatment optimization for Multiple Myeloma: schedule-dependent synergistic cytotoxicity of pomalidomide and carfilzomib in an in vitro and ex-vivo model, file e1dcb335-7a0c-7715-e053-1705fe0a6cc9 65
Role of serum free light chain assay in the detection of early relapse and prediction of prognosis after relapse in multiple myeloma patients treated upfront with novel agents, file e1dcb32f-2aa3-7715-e053-1705fe0a6cc9 63
From transplant to novel cellular therapies in multiple myeloma: EMN guidelines and future perspectives, file e1dcb335-1aa1-7715-e053-1705fe0a6cc9 60
Safety and efficacy of daratumumab in dialysis-dependent renal failure secondary to multiple myeloma, file e1dcb335-52f0-7715-e053-1705fe0a6cc9 60
Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma, file e1dcb339-d8d7-7715-e053-1705fe0a6cc9 59
A NEW RISK STRATIFICATION STRATEGY IN NEWLY DIAGNOSED MULTIPLE MYELOMA: AN ANALYSIS ON MATURE DATA FROM EUROPEAN CLINICAL TRIALS WITHIN THE HARMONY BIG DATA PLATFORM, file e1dcb337-a155-7715-e053-1705fe0a6cc9 58
International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM), file e1dcb337-a004-7715-e053-1705fe0a6cc9 42
2021 European myeloma network review and consensus statement on smoldering multiple myeloma: How to distinguish (and manage) Dr. Jekyll and Mr. Hyde, file e1dcb339-f97b-7715-e053-1705fe0a6cc9 29
Early Light Chains Removal and Albumin Levels with a Double Filter-Based Extracorporeal Treatment for Acute Myeloma Kidney, file 41b7d9a3-e5da-4c86-aa16-3bcdac369bac 25
Identification of a Maturation Plasma Cell Index through a Highly Sensitive Droplet Digital PCR Assay Gene Expression Signature Validation in Newly Diagnosed Multiple Myeloma Patients, file c98b8a6c-52ea-40eb-9081-4d2f4d2811aa 23
Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma, file e1dcb339-aac2-7715-e053-1705fe0a6cc9 20
The ALLgorithMM: How to define the hemodilution of bone marrow samples in lymphoproliferative diseases, file 11e3ddaf-42a3-45f5-9568-708677b17117 15
Safety and efficacy of daratumumab in dialysis-dependent renal failure secondary to multiple myeloma, file e1dcb335-52f1-7715-e053-1705fe0a6cc9 15
Role of serum-free light chain assay for defining response and progression in immunoglobulin secretory multiple myeloma, file eace3be2-8518-47e0-be44-569952f6bb37 14
Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project, file 9a5e4369-643d-4bf3-bddc-2c99bca04acd 12
Real-world analysis of patient characteristics, treatment outcomes, and healthcare resource utilization across Europe in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation who received lenalidomide- or bortezomib-based regimens, file 0e36ca53-48c7-40ef-bf89-e91d49596acf 11
Extramedullary disease in multiple myeloma: a systematic literature review, file 8378c374-6137-417f-8ca9-55a9d5441245 11
Minimal residual disease in Myeloma: Application for clinical care and new drug registration, file 58838ea8-d4fe-479d-8802-4ac5a8c9078b 10
The role of monoclonal antibodies in smoldering and newly diagnosed transplant-eligible multiple myeloma, file 6a7e1c70-0707-401a-8646-2c51e6cfc868 10
Oxytocin Modulates Osteogenic Commitment in Human Adipose-Derived Stem Cells, file 4c3f0734-94a8-4d82-a058-95faba1cb521 9
BoBafit: A copy number clustering tool designed to refit and recalibrate the baseline region of tumors’ profiles, file 688723c0-5171-4371-87ac-6f7b0d0b74e2 9
Inter-Cell Networking Profiling Enables Comprehensive Characterization of Immune-Mediated Activity of Anti-CD38 Therapy through Ex-Vivo Analysis of Multiple Myeloma Patients, file e1dcb337-9eb4-7715-e053-1705fe0a6cc9 9
Role of Imaging in the Evaluation of Minimal Residual Disease in Multiple Myeloma Patients, file f340c0e2-b73c-46bd-bb18-dec091ea5755 9
Positron emission tomography with computed tomography-based diagnosis of massive extramedullary progression in a patient with high-risk multiple myeloma., file e1dcb32c-ea06-7715-e053-1705fe0a6cc9 7
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials, file 1071f612-5177-43ab-a363-861587d0ab2c 5
Monoclonal gammopathy of renal significance (MGRS): Real-world data on outcomes and prognostic factors, file 0fe5d293-6043-4231-b0fb-c52a81f22937 4
Multidisciplinary Management of Sternal Osteomyelitis Due to Klebsiella aerogenes after Open Heart Surgery in a Patient with Multiple Myeloma: A Case Report and Discussion of the Literature, file 1ca893bd-346c-42bf-b6de-3d558f4d40cc 4
Safety of Rapid Daratumumab Infusion: A Retrospective, Multicenter, Real-Life Analysis on 134 Patients With Multiple Myeloma, file c3b44e84-978f-4c77-94c1-755a9e6d37e6 4
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials, file d683cc65-edf1-4f8c-9350-ac021cbdfd06 4
Long term follow-up of humoral and cellular response to mRNA-based vaccines for SARS-CoV-2 in patients with active multiple myeloma, file 30987cd1-61c8-42b7-8afd-bd6ca7056083 3
Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project, file eef44cd6-92cd-4e33-88ab-c4d3611aaf07 3
Pomalidomide combinations are a safe and effective option after daratumumab failure, file 1ef5a7e7-33fb-4064-9a81-d733e5c002c0 2
Severe SARS-CoV-2 and subsequent fungal infections after CAR T-cell therapy for relapsed/refractory multiple myeloma: a challenging and happy ending fight, file 4017cb2b-fbeb-43cb-bf5c-ddac73c50b03 2
Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials, file 4450264b-3039-497d-8a1d-c393984cafb1 2
Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial, file fb7df674-2853-4ea7-8f41-8c230d5b7cbc 2
Pomalidomide combinations are a safe and effective option after daratumumab failure, file fffd26bc-80e4-43bb-b77c-9adf9e6fe033 2
BoBafit: A copy number clustering tool designed to refit and recalibrate the baseline region of tumors’ profiles, file 43a6de1e-c8e5-4306-a5d5-2d81a0a3b57c 1
Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing, file 9a5f77a6-f4c7-461c-9f8c-fac52fdf6249 1
Early use of PEPA dialyzer for light chains removal and for the recovery from myeloma cast nephropathy: A case report, file e1dcb332-d08a-7715-e053-1705fe0a6cc9 1
International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders, file e1dcb334-a433-7715-e053-1705fe0a6cc9 1
Totale 2.476
Categoria #
all - tutte 7.318
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 7.318


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20191 0 0 0 0 0 0 0 0 0 0 1 0
2019/2020111 0 0 0 2 7 6 13 9 19 15 21 19
2020/2021260 16 24 8 16 17 15 14 25 30 30 35 30
2021/2022584 35 31 27 65 62 30 34 31 30 49 140 50
2022/2023697 21 46 122 85 36 35 39 58 87 51 79 38
2023/2024823 26 39 50 76 68 96 108 285 53 22 0 0
Totale 2.476